1017 related articles for article (PubMed ID: 29436178)
21. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
23. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
[TBL] [Abstract][Full Text] [Related]
24. A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients.
Zheng K; Wan H; Zhang J; Shan G; Chai N; Li D; Fang N; Liu L; Zhang J; Du R; Wu Q; Li X; Zhang C
J Transl Med; 2020 May; 18(1):215. PubMed ID: 32466784
[TBL] [Abstract][Full Text] [Related]
25. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
[TBL] [Abstract][Full Text] [Related]
26. Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
Contos G; Baca Y; Xiu J; Brown J; Holloway R; Korn WM; Herzog TJ; Jones N; Winer I
Gynecol Oncol; 2021 Nov; 163(2):312-319. PubMed ID: 34563366
[TBL] [Abstract][Full Text] [Related]
27. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
28. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
[TBL] [Abstract][Full Text] [Related]
29. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
30. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E; Peled N; Nechushtan H; Wollner M; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadari N; Urban D; Mishaeli M; Zer A; Allen AM; Rabinovich NM; Rotem O; Kuznetsov T; Shochat T; Roisman LC; Bar J;
J Thorac Oncol; 2018 Aug; 13(8):1128-1137. PubMed ID: 29723688
[TBL] [Abstract][Full Text] [Related]
31. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
[TBL] [Abstract][Full Text] [Related]
32. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
Wang S; Fang Y; Jiang N; Xing S; Li Q; Chen R; Yi X; Zhang Z; Li N
Front Immunol; 2021; 12():631483. PubMed ID: 33732253
[TBL] [Abstract][Full Text] [Related]
34. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
Kim JH; Park HE; Cho NY; Lee HS; Kang GH
Br J Cancer; 2016 Aug; 115(4):490-6. PubMed ID: 27404452
[TBL] [Abstract][Full Text] [Related]
35. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
Takamochi K; Takahashi F; Suehara Y; Sato E; Kohsaka S; Hayashi T; Kitano S; Uneno T; Kojima S; Takeuchi K; Mano H; Suzuki K
Lung Cancer; 2017 Aug; 110():26-31. PubMed ID: 28676214
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
Gatalica Z; Xiu J; Swensen J; Vranic S
Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
[TBL] [Abstract][Full Text] [Related]
37. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
38. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
[TBL] [Abstract][Full Text] [Related]
39. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
40. Microsatellite instability status is determined by targeted sequencing with MSIcall in 25 cancer types.
Hirotsu Y; Nagakubo Y; Amemiya K; Oyama T; Mochizuki H; Omata M
Clin Chim Acta; 2020 Mar; 502():207-213. PubMed ID: 31730810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
